Literature DB >> 15232619

Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.

Robert A Rissman1, Wayne W Poon, Mathew Blurton-Jones, Salvatore Oddo, Reidun Torp, Michael P Vitek, Frank M LaFerla, Troy T Rohn, Carl W Cotman.   

Abstract

Neurofibrillary tangles (NFTs) are composed of abnormal aggregates of the cytoskeletal protein tau. Together with amyloid beta (Abeta) plaques and neuronal and synaptic loss, NFTs constitute the primary pathological hallmarks of Alzheimer disease (AD). Recent evidence also suggests that caspases are activated early in the progression of AD and may play a role in neuronal loss and NFT pathology. Here we demonstrate that tau is cleaved at D421 (DeltaTau) by executioner caspases. Following caspase-cleavage, DeltaTau facilitates nucleation-dependent filament formation and readily adopts a conformational change recognized by the early pathological tau marker MC1. DeltaTau can be phosphorylated by glycogen synthase kinase-3beta and subsequently recognized by the NFT antibody PHF-1. In transgenic mice and AD brains, DeltaTau associates with both early and late markers of NFTs and is correlated with cognitive decline. Additionally, DeltaTau colocalizes with Abeta(1-42) and is induced by Abeta(1-42) in vitro. Collectively, our data imply that Abeta accumulation triggers caspase activation, leading to caspase-cleavage of tau, and that this is an early event that may precede hyperphosphorylation in the evolution of AD tangle pathology. These results suggest that therapeutics aimed at inhibiting tau caspase-cleavage may prove beneficial not only in preventing NFT formation, but also in slowing cognitive decline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232619      PMCID: PMC437967          DOI: 10.1172/JCI20640

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  80 in total

1.  Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.

Authors:  G A Jicha; R Bowser; I G Kazam; P Davies
Journal:  J Neurosci Res       Date:  1997-04-15       Impact factor: 4.164

2.  Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death.

Authors:  C Stadelmann; T L Deckwerth; A Srinivasan; C Bancher; W Brück; K Jellinger; H Lassmann
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

3.  Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice.

Authors:  O Wirths; G Multhaup; C Czech; V Blanchard; S Moussaoui; G Tremp; L Pradier; K Beyreuther; T A Bayer
Journal:  Neurosci Lett       Date:  2001-06-22       Impact factor: 3.046

4.  Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema.

Authors:  John R Lynch; Jose A Pineda; Duncan Morgan; Lin Zhang; David S Warner; Helen Benveniste; Daniel T Laskowitz
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

5.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

6.  Multiple caspases are activated after traumatic brain injury: evidence for involvement in functional outcome.

Authors:  Susan M Knoblach; Maria Nikolaeva; Xiuling Huang; Lei Fan; Stanislaw Krajewski; John C Reed; Alan I Faden
Journal:  J Neurotrauma       Date:  2002-10       Impact factor: 5.269

7.  Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease.

Authors:  T T Rohn; E Head; J H Su; A J Anderson; B A Bahr; C W Cotman; D H Cribbs
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

8.  Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8.

Authors:  K J Ivins; P L Thornton; T T Rohn; C W Cotman
Journal:  Neurobiol Dis       Date:  1999-10       Impact factor: 5.996

9.  Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.

Authors:  Makoto Higuchi; Takeshi Ishihara; Bin Zhang; Ming Hong; Athena Andreadis; John Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2002-08-01       Impact factor: 17.173

10.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

View more
  217 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 2.  Caspase-mediated degeneration in Alzheimer's disease.

Authors:  David H Cribbs; Wayne W Poon; Robert A Rissman; Mathew Blurton-Jones
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 3.  Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect?

Authors:  Dennis W Dickson
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

4.  Alzheimer disease: caspases first.

Authors:  Jesús Avila
Journal:  Nat Rev Neurol       Date:  2010-11       Impact factor: 42.937

5.  Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer's Disease.

Authors:  María José Pérez; Katiana Vergara-Pulgar; Claudia Jara; Fabian Cabezas-Opazo; Rodrigo A Quintanilla
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

Review 6.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

Review 7.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

8.  Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?

Authors:  Troy T Rohn; Elizabeth Head
Journal:  Int J Clin Exp Pathol       Date:  2008-06-10

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

10.  Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; Eva L Feldman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.